OACP

OaCP provides patented and CE-IVD chemical reagents that reduce times (-97%) and costs (-50%) of DNA tests for cancer diagnosis. OaCP addresses the Molecular in vitro diagnostics market, starting from the high competitive USD 1b In situ Hybridization one, reaching USD 100K in sales with 100% of CRR and 98% of GM to hospitals and R&D centres. OaCP takes advantage also from a distribution network that covers almost 15 countries globally. Driven by a team with complementary skills in Science, Busin... ess, Marketing and Web communication, OaCP undergone to the RebelBio Accelerator program in 2017, receiving, up to today, USD330k in funding mainly from SOS Venture. OaCP has been awarded in several international competition mainly in Hong Kong and China. Now OaCP is looking for an investment on Euro 2M to push, expand and consolidate the market presence, to create a company able to grow organically to bring to the greatest number of cancer patients the best diagnostic technology.More